Primary Medical Therapy for Acromegaly: An Open, Prospective, Multicenter Study of the Effects of Subcutaneous and Intramuscular Slow-Release Octreotide on Growth Hormone, Insulin-Like Growth Factor-I, and Tumor Size-Reference-Cited by-同舟云学术

Primary Medical Therapy for Acromegaly: An Open, Prospective, Multicenter Study of the Effects of Subcutaneous and Intramuscular Slow-Release Octreotide on Growth Hormone, Insulin-Like Growth Factor-I, and Tumor Size

Published:2002-10-01 Issue:10 Volume:87 Page:4554-4563
ISSN:0021-972X
Container-title:The Journal of Clinical Endocrinology & Metabolism
language:en
Short-container-title:

Author:

Bevan J. S.¹,Atkin S. L.²,Atkinson A. B.³,Bouloux P.-M.⁴,Hanna F.⁵,Harris P. E.⁶,James R. A.⁷,McConnell M.³,Roberts G. A.⁶,Scanlon M. F.⁵,Stewart P. M.⁸,Teasdale E.⁹,Turner H. E.¹⁰,Wass J. A. H.¹⁰,Wardlaw J. M.¹¹

Affiliation:

1. Department of Endocrinology, Aberdeen Royal Infirmary (J.S.B.), Aberdeen, United Kingdom AB25 2ZN;

2. Department of Endocrinology, Hull Royal Infirmary (S.L.A.), Hull, United Kingdom HU3 3KZ;

3. Department of Endocrinology, Royal Victoria Hospital (A.B.A., M.M.), Belfast, United Kingdom BT12 6BA;

4. Department of Endocrinology, Royal Free Hospital (P.-M.B.), London, United Kingdom NW3 2QQ;

5. Department of Endocrinology, University Hospital of Wales (F.H., M.F.S.), Cardiff, United Kingdom CF4 4XN;

6. Department of Endocrinology, Kings’ College Hospital (P.E.H., G.A.R.), London, United Kingdom SE5 9RS;

7. Department of Endocrinology, Royal Victoria Infirmary (R.A.J.), Newcastle-upon-Tyne, United Kingdom NE1 4LP;

8. Department of Endocrinology, Queen Elizabeth Hospital (P.M.S.), Birmingham, United Kingdom B15 2TH;

9. Department of Neuroradiology, Southern General Hospital (E.T.), Glasgow, United Kingdom G51 4TF;

10. Department of Endocrinology, Radcliffe Infirmary (H.E.T., J.A.H.W.), Oxford, United Kingdom OX2 6HE;

11. Department of Neuroradiology, Western General Hospital (J.M.W.), Edinburgh, United Kingdom EH4 2XU

Publisher

The Endocrine Society

Subject

Biochemistry (medical),Clinical Biochemistry,Endocrinology,Biochemistry,Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jcem/article-pdf/87/10/4554/9155304/jcem4554.pdf

Reference22 articles.

1. Current therapy for acromegaly.;Stewart;Trends Endocrinol Metab,2000

2. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly.;Swearingen;J Clin Endocrinol Metab,1998

3. Outcome of transphenoidal surgery for acromegaly and its relationship to surgical experience.;Ahmed;Clin Endocrinol (Oxf),1999

4. Effects of pre-operative octreotide treatment on different subtypes of 90 growth hormone secreting pituitary adenomas and outcome in one surgical centre.;Abe;Eur J Endocrinol,2001

5. Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure.;Sheaves;Clin Endocrinol (Oxf),1996

Cited by 246 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigation of the Relationship between Adenoma Volume and Perioperative Hormone Levels in Patients with Acromegaly;European Journal of Therapeutics;2023-09-17

2. Age, GH/IGF-1 levels, tumor volume, T2 hypointensity, and tumor subtype rather than proliferation and invasion are all reliable predictors of biochemical response to somatostatin analogue therapy in patients with acromegaly: A clinicopathological study;Growth Hormone & IGF Research;2022-12

3. Acromegaly: pathogenesis, diagnosis, and management;The Lancet Diabetes & Endocrinology;2022-11

4. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial;The Lancet Diabetes & Endocrinology;2022-02

5. Acromegaly;Pituitary Adenomas;2022